Caroverine hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: Caroverine hydrochloride
• 英文别名: 1-(2-diethylaminoethyl)-3-(p-methoxybenzyl)-1,2-dihydroquinoxalin-2-one hydrochloride；Diethyl-[2-[3-[(4-methoxyphenyl)methyl]-2-oxoquinoxalin-1-yl]ethyl]azanium;chloride；diethyl-[2-[3-[(4-methoxyphenyl)methyl]-2-oxoquinoxalin-1-yl]ethyl]azanium;chloride
• 化学式: C₂₂H₂₇N₃O₂*ClH
• 分子量: 401.936
• InChiKey: JRNWTJUIMRLKBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.76
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  45.1
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• MANUFACTURING METHOD AND APPARATUS OF ULTRAFINE PARTICLES HAVING UNIFORM PARTICLE SIZE DISTRIBUTION
  申请人：Hwang Sung Joo

  公开号：US20110200678A1

  公开（公告）日：2011-08-18

  The present invention relates to a novel technology for forming fine particles with a size of 0.02˜3 microns from a solid that can be dissolved in a liquid solvent and is not decomposed by heat. The particle preparation technology according to the present invention may be applicable to the fields of food, cosmetics, biopolymer, polymer compositions, and pharmaceuticals.

  本发明涉及一种新型技术，用于从可溶于液体溶剂且不会被热分解的固体中形成粒径为0.02〜3微米的细小颗粒。本发明的颗粒制备技术可适用于食品、化妆品、生物聚合物、聚合物组合物和制药等领域。
• Pharmaceutical composition comprising 7β-hydroxycholesterol intravenous administration
  申请人：Immunopharm AG

  公开号：US10179138B2

  公开（公告）日：2019-01-15

  The present invention relates to a pharmaceutical composition comprising (a) 7β-hydroxycholesterol, (b) a water soluble organic solvent, preferably propylene glycol and/or DMSO, and (c) a solubilizing agent, preferably PEG hydrated castor oil, and to a method for preparing the same. This composition is suitable for preparing an intravenously administered preparation and comprises the pharmaceutically active substance β-hydroxycholesterol, which is poorly soluble in water.

  本发明涉及一种药物组合物，其中包括：(a) 7β-羟基胆固醇；(b) 水溶性有机溶剂，最好是丙二醇和/或二甲基亚砜；(c) 增溶剂，最好是 PEG 水合蓖麻油；本发明还涉及一种制备方法。该组合物适用于制备静脉注射制剂，包含药用活性物质 β-羟基胆固醇，该物质在水中的溶解度很低。
• Use of 1- (aminoalkyl) -3-quinoxaline-2-on derivatives for the preparation of compounds having an antioxidant action
  申请人：——

  公开号：US20010006966A1

  公开（公告）日：2001-07-05

  The invention relates to the use of 1-(aminoalkyl)-3-quinoxaline-2-one derivatives, especially 1-diethylaminoethyl-3-quinoxaline-2-one derivatives of the formula (I), where R 3 is hydroxy, methoxy, ethoxy or hydrogen, or pharmaceutically compatible salts thereof, for the preparation of compounds having an antioxidant action and used for preventing or treating diseases caused by free radicals of the cellular oxygen metabolism, stimulating nerve cell growth, antagonizing glutamate receptors and/or stimulating the growth notably of glutamergic nerve cells.

  本发明涉及 1-(氨基烷基)-3-喹喔啉-2-酮衍生物，特别是式(I)中 R 3 为羟基、甲氧基、乙氧基或氢的 1-二乙氨基乙基-3-喹喔啉-2-酮衍生物或其药用盐的用途、用于制备具有抗氧化作用的化合物，并用于预防或治疗由细胞氧代谢自由基引起的疾病、刺激神经细胞生长、拮抗谷氨酸受体和/或明显刺激谷氨酸能神经细胞的生长。
• Pharmaceutical Composition Comprising 7 Beta -Hydroxycholesterol Intravenous Administration
  申请人：Immunopharm AG

  公开号：US20170196894A1

  公开（公告）日：2017-07-13

  The present invention relates to a pharmaceutical composition comprising (a) 7β-hydroxycholesterol, (b) a water soluble organic solvent, preferably propylene glycol and/or DMSO, and (c) a solubilizing agent, preferably PEG hydrated castor oil, and to a method for preparing the same. This composition is suitable for preparing an intravenously administered preparation and comprises the pharmaceutically active substance β-hydroxycholesterol, which is poorly soluble in water.
• US6573265B2
  申请人：——

  公开号：US6573265B2

  公开（公告）日：2003-06-03